Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/nbt.3235 http://scihub22266oqcxt.onion/10.1038/nbt.3235 C4529991!4529991!25961408     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nat+Biotechnol 2015 ; 33 (6): 661-7 Nephropedia Template TP {{tp|p=25961408|t=2015. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains |pdf=|usr=}}{{25961408}} gab.com Text Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains JO: Nat Biotechnol http://www.kidney.de/pget.php?&tw=1&pmid=25961408 #FOAvip CRISPR-Cas9 genome editing technology holds great promise for discovering therapeutic targets in cancer and other diseases. Current screening strategies target CRISPR-induced mutations to the 5? exons of candidate genes1?5, but this approach often produces in-frame variants that retain functionality, which can obscure even strong genetic dependencies. Here we overcome this limitation by targeting CRISPR mutagenesis to exons encoding functional protein domains. This generates a higher proportion of null mutations and substantially increases the potency of negative selection. We show that the magnitude of negative selection reports the functional importance of individual protein domains of interest. A screen of 192 chromatin regulatory domains in murine acute myeloid leukemia cells identifies six known drug targets and 19 additional dependencies. A broader application of this approach may allow comprehensive identification of protein domains that sustain cancer cells and are suitable for drug targeting. Twit Text FOAVip Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains ????Nat Biotechnol http://www.kidney.de/pget.php?&tw=1&pmid=25961408 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25961408 #FOAvip English Wikipedia <ref>{{Cite pmid|25961408}}</ref> Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains #MMPMID25961408 Shi J; Wang E; Milazzo JP; Wang Z; Kinney JB; Vakoc CR Nat Biotechnol 2015[Jun]; 33 (6): 661-7 PMID25961408show ga CRISPR-Cas9 genome editing technology holds great promise for discovering therapeutic targets in cancer and other diseases. Current screening strategies target CRISPR-induced mutations to the 5? exons of candidate genes1?5, but this approach often produces in-frame variants that retain functionality, which can obscure even strong genetic dependencies. Here we overcome this limitation by targeting CRISPR mutagenesis to exons encoding functional protein domains. This generates a higher proportion of null mutations and substantially increases the potency of negative selection. We show that the magnitude of negative selection reports the functional importance of individual protein domains of interest. A screen of 192 chromatin regulatory domains in murine acute myeloid leukemia cells identifies six known drug targets and 19 additional dependencies. A broader application of this approach may allow comprehensive identification of protein domains that sustain cancer cells and are suitable for drug targeting. äDiscovery of cancer drug targets by CRISPR-Cas9 screening of protein d(epmc).pdf DeepDyve Pubget Overpricing